Research programme: cancer therapeutics - EPI Pharmaceuticals

Drug Profile

Research programme: cancer therapeutics - EPI Pharmaceuticals

Alternative Names: PG-11000 Series; PG-11093; PG-11100 Series; PG-11122; PG-11144; SL11217; SL11218; SL11231; SL11237

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cellgate
  • Developer EPI Pharmaceuticals
  • Class Naphthoquinones; Polyamines; Porphyrins; Quinones
  • Mechanism of Action Apoptosis stimulants; Cell division inhibitors; Histone deacetylase inhibitors; Lysine specific demethylase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (IV)
  • 14 Dec 2011 Progen Pharmaceuticals completes EPI Pharmaceuticals formation and transfers the epigenetic and cell proliferation assets to EPI
  • 25 Feb 2011 Progen's cancer therapeutics are still at the preclinical stage for Cancer in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top